| Index | — | P/E | — | EPS (ttm) | -2.48 | Insider Own | 18.04% | Shs Outstand | 39.24M | Perf Week | 0.36% |
| Market Cap | 870.78M | Forward P/E | — | EPS next Y | -3.01 | Insider Trans | -1.91% | Shs Float | 35.55M | Perf Month | -10.52% |
| Enterprise Value | 633.78M | PEG | — | EPS next Q | -0.67 | Short Float | 14.64% | Perf Quarter | -21.40% | ||
| Income | -84.00M | P/S | — | EPS this Y | — | Short Ratio | 9.64 | Perf Half Y | -11.91% | ||
| Sales | 0.00 | P/B | 3.98 | EPS next Y | — | ROA | -33.16% | Short Interest | 5.20M | Perf YTD | 24.66% |
| Book/sh | 5.58 | P/C | 3.57 | EPS next 5Y | — | ROE | -46.46% | 52W High | 37.48 -40.80% | Perf Year | 54.96% |
| Cash/sh | 6.22 | P/FCF | — | EPS past 3/5Y | — | ROIC | 18.43% | 52W Low | 10.20 117.55% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 5.95% 6.11% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.52 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 14.85 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 37.91 | Recom | 2.11 |
| Dividend Gr. 3/5Y | — | Current Ratio | 14.85 | EPS Q/Q | 0.00% | SMA20 | -3.47% | Beta | 1.73 | Target Price | 39.25 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | — | SMA50 | -20.84% | Rel Volume | 0.84 | Prev Close | 22.60 |
| Employees | 68 | LT Debt/Eq | 0.01 | Earnings | Nov 11 | SMA200 | -8.61% | Avg Volume | 564.75K | Price | 22.19 |
| IPO Date | Feb 02, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 11.51% — | Net Debt/EBITDA | — | Volume | 473,275 | Change | -1.81% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | HC Wainwright & Co. | Buy | $55 → $60 |
| Aug-17-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $55 |
| Aug-13-26 | Reiterated | BTIG | Buy | $28 → $37 |
| May-27-26 | Reiterated | H.C. Wainwright | Buy | $50 |
| May-18-26 | Reiterated | Robert W. Baird | $38 → $36 | |
| May-14-26 | Reiterated | Wedbush | Neutral | $24 |
| Mar-16-26 | Reiterated | Jefferies | Buy | $35 |
| Feb-17-26 | Reiterated | BTIG | Buy | $28 |
| Oct-20-25 | Reiterated | Robert W. Baird | $10 → $16 | |
| Oct-23-24 | Reiterated | Robert W. Baird | $32 → $10 |
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | 1 | 0 | — | — | |
| Gross Profit | 0 | -1 | -1 | 0 | — | — | |
| Selling, General and Administrative Excl. Other | 23 | 21 | 22 | 8 | — | — | |
| Research and Development | 65 | 46 | 47 | 30 | — | — | |
| Other Operating Expense | -133 | -1 | -1 | 0 | — | — | |
| Operating Income | 45 | -66 | -69 | -38 | — | — | |
| Interest Expense | 3 | 2 | -1 | 1 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -127 | 6 | 6 | 3 | — | — | |
| Net Income Before Taxes | -84 | -63 | -61 | -36 | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -84 | -63 | -61 | -36 | — | — | |
| Net Income From Continuing Operations | -84 | -63 | -61 | -36 | — | — | |
| Net Income | -84 | -63 | -61 | -36 | — | — | |
| EPS (Recurring) | -2.48 | -2.19 | -2.50 | -1.35 | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.48 | -2.19 | -2.50 | -1.35 | — | — | |
| EPS (Diluted) | -2.48 | -2.19 | -2.50 | -1.35 | — | — | |
| EBITDA | -81 | -60 | -62 | -35 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 43 | 29 | 25 | 27 | — | — | |
| Market Capitalization | 954 | 516 | 106 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Smith Nicholas Conrad | PRESIDENT AND CFO | Oct 02 '26 | Option Exercise | 2.32 | 55,000 | 127,600 | 79,060 | Oct 05 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 30 '26 | Sale | 25.82 | 24,056 | 621,097 | 24,060 | Oct 01 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 30 '26 | Option Exercise | 2.35 | 24,056 | 56,532 | 48,116 | Oct 01 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 29 '26 | Option Exercise | 2.35 | 110,830 | 260,450 | 134,890 | Oct 01 |
| Smith Nicholas Conrad | PRESIDENT AND CFO | Sep 29 '26 | Sale | 26.58 | 110,830 | 2,946,150 | 24,060 | Oct 01 |
| Savitz Adam | CHIEF MEDICAL OFFICER | Jul 10 '24 | Buy | 13.22 | 2,931 | 38,748 | 39,851 | Jul 11 |
| Savitz Adam | CHIEF MEDICAL OFFICER | Jul 09 '24 | Buy | 12.60 | 12,069 | 152,085 | 36,920 | Jul 11 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER | Mar 28 '24 | Buy | 16.36 | 6,150 | 100,628 | 26,866 | Apr 01 |
| Alpha Wave Global, LP | 10% Owner | Feb 06 '24 | Buy | 16.00 | 600,000 | 9,600,000 | 3,707,757 | Feb 08 |
| Smith Nicholas Conrad | CHIEF FINANCIAL OFFICER | Feb 06 '24 | Buy | 16.00 | 1,563 | 25,008 | 1,563 | Feb 07 |
| Savitz Adam | CHIEF MEDICAL OFFICER | Feb 06 '24 | Buy | 16.00 | 17,000 | 272,000 | 24,851 | Feb 07 |
| Etkin Amit | PRESIDENT AND CEO | Feb 06 '24 | Buy | 16.00 | 3,125 | 50,000 | 1,205,465 | Feb 07 |